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AN IN VIVO IMPROVEMENT OF RANGE OF MOTION IN SHOULDER 
CONTRACTURES WITH RELAXIN IN ANIMAL MODELS  
STEPHEN M. OKAJIMA 
ABSTRACT 
Introduction 
 Arthrofibrosis, which occurs in a substantial portion of the population, is a 
pathologic accumulation of scar tissue that presents in patients as a painful decrease in 
joint range of motion. Since an individual’s quality of life can be significantly impacted 
by arthrofibrosis and because there are limitations in current treatments, this thesis 
focuses on examining the use of the hormone relaxin to alleviate shoulder arthrofibrosis.  
Methods 
 A set of 20 Sprague Dawley rats were given secondary shoulder contractures and 
separated into groups to examine the efficacy of relaxin using intravenous delivery, intra-
articular delivery, and different treatment frequencies. The differences across groups 
were examined through mechanical range of motion testing as well as histologic 
sampling.  
Results 
 Multiple doses of intra-articular injections of relaxin showed a complete return to 
the normal range of motion (P < 0.01) when compared with the surgical control, whereas 
other delivery methods and frequencies failed to show meaningful improvements. This 
was further confirmed in histologic analysis through the lack of fibrotic adhesions within 
  vi 
the capsular space after multiple intra-articular relaxin treatments when compared with 
the surgical control.  
Discussion 
 Although significant improvements to range of motion were seen after multiple 
doses of intra-articular relaxin, potential tissue degradation was also observed within the 
joint space after histologic examination. Further research is necessary to fully understand 
the proper dosing needed to avoid potential negative side effects caused by excess use of 
relaxin.  
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INTRODUCTION 
Background of Arthrofibrosis 
 Arthrofibrosis presents a significant public health issue with limited and varied 
outcomes given current treatment options. Arthrofibrosis is defined as a pathologic 
accumulation of excessive scar tissue or adhesions found within or around a joint space. 
The excessive scar tissue results in a painful, gradual restriction of passive and active 
range of motion (ROM) (1-3). Development of arthrofibrosis is still unclear and is 
thought to arise through synovitis, trauma or injury, or prolonged immobilization of the 
joint. The disease may also occur idiopathically (1, 4). Those affected by arthrofibrosis 
observe a direct impact on their quality of life, with their afflicted joint making daily 
tasks more difficult. This disease may occur in any joint and affects articular areas such 
as the hip, ankle, wrist, elbow, and most notably the knee and shoulder.  
Within the knee, arthrofibrosis that necessitated surgical intervention after 
articular fractures or post-intra-articular trauma was reported at 14.5% incidence (5). 
After anterior cruciate ligament (ACL) reconstruction, the incidence was reported to be 
as high as 35% (6). Further, the incidence of arthrofibrosis after a total knee arthroplasty 
was close to 15% (7). With regard to arthrofibrosis within the shoulder, in a random 
sampling of ten thousand individuals, 8.2% of men and 10.1% of women were shown to 
have some degree of arthrofibrosis (8). It is estimated that arthrofibrosis of the shoulder 
has an incidence between 2% and 5% of the general population, with  20%-36% 
prevalence within those suffering from diabetes (1, 9-12).  
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 Treatment options are similar across the different joint cases and do little to 
improve patient outcomes. Nonoperative treatments include physical therapy, 
nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroid injections, 
intra-articular sodium hyaluronate injections, and nerve blocks. Although these methods 
may aid to provide moderate or temporary relief from the symptoms, they are only 
marginally effective (1, 4). In more extreme cases, surgical intervention may prove to 
alleviate the patient from symptoms of arthrofibrosis. These procedures include 
manipulation under anesthesia (MUA), arthroscopic capsulotomy, and more rarely an 
open capsulotomy. Whereas an open capsulotomy was shown to do little to improve 
ROM and pain, arthroscopic capsulotomies and MUA were shown to improve ROM and 
reduce pain; however, they may also cause complications that can worsen the condition 
(1).   
Since arthrofibrosis covers a wide range of pathologies, it is helpful to limit the 
focus of this study to a single type of arthrofibrosis. The priority of this thesis is to 
examine a potential treatment for arthrofibrosis within the shoulder. Although the above 
treatment options are available to patients with arthrofibrosis, there remains a need for a 
treatment that more completely targets the symptoms or the causes of the disease.  
 
Pathologic and Epidemiologic Significance Within the Shoulder 
 Arthrofibrosis of the shoulder, also known as shoulder contracture, adhesive 
capsulitis, or more colloquially frozen shoulder, is characterized by a progressive fibrosis 
and contracture of the capsule within the shoulder, leading to a reduction in both active 
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and passive glenohumeral motion (Figure 1) (13). This disease manifests typically after 
trauma, prolonged immobilization, or synovitis of the affected area. It may also occur 
idiopathically. Pathologically, this disease is established as an increased deposition of 
type I and type III collagen matrix from an increased recruitment of fibroblastic and 
myofibroblastic cells to the area of injury (14, 15). Even though the presence of important 
inflammatory mediators and mechanisms, such as T cells, B cells, synovial cells, 
fibroblasts, and transforming myofibroblasts, have been shown to exist in patients 
undergoing surgical capsular release, the exact manner of causation has yet to be 
discovered.  
  
Figure 1. Anatomy of a frozen 
shoulder. The illustration shows 
the anatomy of the glenohumeral 
joint and the affected areas within 
the joint for cases of adhesive 
capsulitis. The intra-articular space 
is also known as the synovial space 
or the space within the joint. 
Adapted from Harvard Medical 
School, 2014 (16). 
 
 
 
 
 
 Shoulder contracture can be classified as either primary (idiopathic) or secondary 
(known extrinsic/intrinsic cause), and both cause a significant reduction in ROM (17, 18). 
In the general population, women are known to be more often affected by shoulder 
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contracture than men, but there is no known genetic or racial correlation (19). 
Macroscopically, capsular contracture is identified as a thickened joint capsule with 
adhesions interfering with the axillary fold. The fibrotic capsule can then adhere to itself 
and the anatomic neck of the humerus, causing a decrease in the intra-articular volume 
and thus reducing the amount of synovial fluid within the joint (20).  
Of the 2% to 5% of the population afflicted with adhesive capsulitis (11, 12), a 
majority of that population is subdivided into the ages of 40-60 years (19). Adhesive 
capsulitis is often seen as a self-limiting disease, with patients regaining mobility within 1 
to 3 years. However, a significant number of patients never regain a full normal range of 
mobility (21). Although there are instances in which patients achieve a spontaneous 
resolution and attain full ROM, up to 60% have a lasting reduction in ROM, and 50% 
have residual pain for several years after the onset of the disease (22). As with other 
arthrofibrotic joints, treatments through physical therapy are often long and painful and 
still fail to resolve this issue.  
 
Current Treatments and their Effectiveness in Shoulder Arthrofibrosis 
Nonsurgical Interventions 
 Nonsurgical interventions for capsular fibrosis vary widely in their effectiveness 
but are ultimately lacking in their ability to treat the disease. Physical therapy is generally 
used as the first line of treatment for those that have early stages of a shoulder contracture 
(1). However, physical therapy as an individual treatment has little support showing its 
efficacy (23). Although the core motivation behind physical therapy is early mobilization, 
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there remains to be seen a consensus in both frequency and intensity for the treatment. 
One study reported that 63% of their patients who underwent intense physical therapy 
improved when compared with 90% of those who did gentler therapy, whereas another 
study performed by Vermeulen et al. (24)showed no difference between therapy 
intensities (1, 24, 25). Despite the improvements within patients common across studies, 
other studies have shown no differences between those that received physiotherapy and 
those that did not (4). 
 NSAIDs can also be prescribed to treat adhesive capsulitis. Since COX-1 and 
COX-2 have elevated expression within the capsular and bursal tissues, anti-
inflammatory drugs prove to reduce pain by targeting the inflammatory pathway (26).  
This is often beneficial when used in conjunction with physical therapy, as pain 
management encourages the pursuit of additional activity. However, when used alone, the 
anti-inflammatory treatment does little more than improve the pain associated with the 
contracture (27). An alternative pharmacological therapy, intra-articular corticosteroid 
injections, has shown to provide reductions in fibromatosis and myofibroblasts within 
shoulder contractures. In one study, it was shown that intra-articular methylprednisolone 
injections resulted in initial improvements in ROM and pain beyond that of physical 
therapy, ice therapy, and no therapy groups (28). This improvement was short-lived, 
however, as there was unfortunately no difference between all groups after 6 months. 
Another injection type, sodium hyaluronate, is used because it can be chondro-protective. 
This unbranched polysaccharide was shown to produce similar outcomes as intra-
articular injections of corticosteroid (29).  
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 Other nonsurgical interventions include suprascapular nerve blocks (SSNB) and 
hydrodilation. The SSNB works by reducing pain perceived at the shoulder, since 70% of 
the glenohumeral joint nerve supply originates from the suprascapular nerve (30). Of 
course, this improves pain in the short-term but fails to improve ROM (31).  
Hydrodilation, or distention arthrography, is a process in which the capsular space is 
dilated through injection of air or fluid under fluoroscopic guidance. This procedure aims 
to stretch the capsule, under anesthesia, to counteract the contracted capsule (32, 33). 
Hydrodilation was shown to provide similar improvement in pain and ROM with both 
injection of normal saline and a corticosteroid-infused saline; however, this improvement 
was similar to that observed in intra-articular corticosteroid injections (34).  
 
Surgical Interventions 
 When patients do not respond well to conservative treatments, surgical 
intervention is possible. These interventions, however, do not come without downsides. 
MUA for the shoulder aims to tear the capsular adhesions under a controlled setting 
beyond the limits imposed by pain on a patient. Although MUA is considered a safe 
procedure, cases of hemathrosis, capsular tear, labral detachment, superior labral anterior 
and posterior lesions, and humeral or glenoid fracture have been known to occur (35-37). 
The effectiveness of this treatment is still debated, as some studies have shown moderate 
improvement in pain and ROM, whereas other studies have shown worse outcomes than 
other nonsurgical therapies (38, 39). MUA is also less effective in those with diabetes 
(40).  
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 A more effective procedure is an arthroscopic capsulotomy which comes with two 
advantages. An initial diagnostic arthroscopy can be performed to confirm the presence 
and exact location of the fibrosis while simultaneously ruling out other potential causes 
for shoulder pain. In this way, a capsular release can be performed directly at the area of 
interest (41-43). Multiple studies have shown improvements in most, if not all, patients 
who have undergone arthroscopic capsulotomies, which are usually concluded with little 
complication (44-46).  Although generally safe, infection of postoperative arthrofibrosis 
can occur. Unfortunately, while diabetic patients show slight improvements, they do not 
show the same improvement as seen in nondiabetic patients (47).  On the other hand, 
open capsulotomies are rarely performed because of the increased time required for 
postoperative recovery, although they achieve a similar effect to the arthroscopic variant 
(1, 48, 49). While these surgical procedures may be effective, their invasiveness and 
potential for complication underline the need for a more efficient therapy for shoulder 
arthrofibrosis.  
 
Biochemical Basis for Relaxin 
 Capsular fibrosis is highlighted by an excessive accumulation of extracellular 
matrix (ECM) components, including fibrillary collagens type I and type III, as a result of 
expression of transforming growth factor beta (TGF-𝛽), a potent fibrogenic agent. A 
decreased clearance of ECM components also occurs because of decreased secretion of 
matrix metalloproteinases (MMPs) (13, 14, 50). These MMPs are important for their 
degradation of collagen and their subsequent role in increasing the endogenous inhibitors, 
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tissue inhibitors of metalloproteinases (TIMPs). These interactions are normal in a 
healing response after an injury to tissue. However, if these interactions are not stopped, a 
simultaneous decrease in clearance and an increased production of ECM result in 
excessive tissue scarring (50).  Thus, the contracted capsule has a mechanical resistance 
to motion while causing pain from inflammation. Additionally, gene and protein 
expression assays have found products related to fibrosis, inflammation, and 
chondrogenesis, including increased collagen type I alpha 1 (COL1A1) and collagen type 
I alpha 3 (COL1A3) genes, interleukin-6, platelet-derived growth factor (PDGF), and 
fibroblast growth factors (FGF) (51). This information further suggests that inflammatory 
changes initiate the recruitment of fibroblasts and immune cells, encouraging the fibrotic 
process and an inappropriate deposition of collagen. However, an alternative idea is that 
fibrotic changes occur before inflammation, making fibrosis the underlying disease 
process. In this model, it is thought that the error lies within the defective cell signaling 
pathways that mediate collagen remodeling (52).   
Relaxin is a 6-kDa hormone, derived from the insulin superfamily, that naturally 
plays a role in inhibiting uterine contractions and assists in cervical dilation during 
pregnancy by aiding to soften and grow the cervix (50). Similar to insulin, relaxin is 
processed from a prepro-form to the mature hormone-containing A and B peptide chains, 
which are connected by two interchain disulfide bridges and one intrachain disulfide 
within the A chain (53). However, relaxin is also an antifibrotic hormone that causes an 
increase in MMPs and fibronectin degradation while simultaneously decreasing the 
expression of TIMPs and TGF-𝛽-induced fibronectin levels (54-56). With this 
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understanding, it may be possible that the use of relaxin may reduce or reverse the 
biochemical effects of a capsular contracture if a reliable delivery method can be 
developed. Recently, a highly purified recombinant form of H2 relaxin, or relaxin 2, has 
been tested in many in vitro and in vivo systems to evaluate both its ability to modify 
connective tissue and its potential antifibrotic properties. So far, several studies have 
reported that relaxin acts at multiple levels to inhibit collagen overexpression and 
fibrogenesis within pulmonary, renal, cardiac, and hepatic environments (50). What is yet 
to be seen, however, is whether relaxin can be delivered to maximize an efficacy to 
alleviate the symptoms related to shoulder arthrofibrosis.  
Because relaxin has a half-life of only 2.5 hours when delivered intravenously 
(57), it is difficult to say how relaxin should be most effectively administered to affect the 
joint space. To investigate the most successful method of delivery, this thesis will 
examine multiple methods of both different temporal dosing and different administration 
locations.  It is therefore hypothesized that the effective delivery of relaxin will increase 
the ROM, in addition to reducing pain, in those diagnosed with shoulder contracture. 
Furthermore, it is thought that an intra-articular injection of relaxin will shield the protein 
from normal systemic degradation, extending its half-life, and that multiple injections 
will be required to maintain a level necessary to reverse the fibrosis.  
 
Animal Model and Hypothesis Testing 
 This hypothesis will be tested in a rat model based on an induction of frozen 
shoulder through a prolonged extra-articular internal fixation of the shoulder (see Figure 
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2) (58), which mimics the clinical observations with shoulder contracture.  This model 
has demonstrated the same long-lasting effects to the joint mechanics within the shoulder 
that are of interest for this study.  Additionally, the synovial hyperplasia related to an 
increased content of type III collagen is also observed (59).  This model also reliably 
reproduces a decrease in ROM in both internal and external rotational directions, a 
characteristic of the clinical manifestation of shoulder contracture in humans.  
 
Figure 2. Representation of the animal model 
for extra-articular, internal fixation of the 
glenohumeral joint. Braided polyester sutures 
are tied around the humerus and through the 
inferior border of the scapula and tightened to 
restrict movement. This method avoids any major 
vessels and nerves while providing maximal 
restriction. Adapted from Villa-Camacho et al., 
2015 (58). 
 
 
 
With a reliable animal model and the same robotic testing apparatus (58), the 
change in ROM will be observed over time following a similar 8-week immobilization 
period under different conditions for relaxin exposure. Furthermore, immunohistology 
will be performed on samples taken from the rats to observe the effects of relaxin on 
collagen I, collagen III, and MMP expressions within the joint. These samples will also 
be evaluated for anatomic changes due to excessive fibrosis, or lack thereof. Because it is 
possible for symptoms of frozen shoulder to spontaneously resolve, the rate of this 
occurrence, as well as the degree to which the rats return to normalcy, will be examined.  
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Goals and Specific Aims 
To reliably determine whether relaxin affects the transient outcome of those 
diagnosed with frozen shoulder, an animal model will be used to address the following 
aims:  
Aim 1: Determine whether the location of injection of relaxin, either intra-articular or 
systemic, significantly affects the prognosis of ROM in the rat model.  
Aim 2: Determine whether a single injection or prolonged exposure to relaxin has any 
appreciable effect on prognosis.  
Aim 3: Examine the effects of relaxin on the glenohumeral joint capsule and 
histologically compare those results to controls.  
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METHODS  
Specimen Preparation 
 On the approval of the Institutional Animal Care and Use Committee (IACUC), 
20 Sprague Dawley rats (250-300 g, Charles River Laboratories, Inc., Wilmington, MA, 
USA) were chosen for this study. Before the rats were immobilized to create adhesive 
capsulitis, baseline ROM measurements were taken for both forelimbs. Torque 
measurements were recorded at 100o of internal rotation (𝜏𝐼𝑁𝑇) and 60
o of external 
rotation (𝜏𝑂𝑈𝑇) (Figure 3). These measurements were required as they indicate a baseline 
for normal torque necessary to achieve both rotations. These angles were chosen to 
ensure minimal scapular recruitment while simultaneously providing maximum humeral 
rotation within the joint space. Scapular deviation was monitored through fluoroscopy. 
Each ROM measurement was repeated three times to ensure consistency. These 
measurements were also performed under anesthesia to prevent any active muscle 
activation from interfering with the passive capsular resistance. Induction of the rats was 
performed at 5% isoflurane inhalation, and maintenance was managed at a 2% isoflurane 
dose. 
After the baseline measurements and while still anesthetized, the 20 rats were 
subjected to the immobilization procedure as outlined in Villa-Camacho et al. (58) to 
induce fibrosis. On the left limb, an incision was created longitudinally, perpendicular to 
the scapular spine to expose both the scapula and humerus. A No. 2-0 Ethibond polyester 
suture (Ethicon, San Lorenzo, PR, USA) was used to immobilize the humerus to the 
scapula by passing two loops through the medial border of the scapula and against the 
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humeral shaft (Figure 2). Care was taken to ensure the sutures avoided critical 
vasculature, musculature, and nerves. Each rat was maintained under fixation for 8 
weeks. After the eighth week, the suture fixations were removed, and the rats were 
randomly placed in four groups: (1) intra-articular relaxin, single dose (n = 5); (2) intra-
articular relaxin, multiple doses (n = 5); (3) intravenous relaxin, multiple doses (n = 5); 
and (4) untreated controls (n = 5).  
 
 
Figure 3. Range of motion measurement apparatus and method. (A) The core components of 
the range of motion measurement apparatus and measurement method are: (a) stepper motor, (b) 
torque sensor, (c) inclinometer, and (d) arm clamp. Rotation of the rat forelimb is shown in 
internal (B) or external (C) rotation of 100o and 60o, respectively. Adapted from Villa-Camacho 
et al., 2015 (58).  
 
Mechanical Testing Apparatus  
 The mechanical testing apparatus was assembled with four core components and 
controlled with a computer through custom-built software written on MATLAB 
7.13.0.564 (The MathWorks, Inc., Natick, MA, USA). Movement of the forelimb was 
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mediated by a stepper motor controlled by a microcontroller (UNO R3; Arduino, Torino, 
Italy). The motor was then positioned axially with the reaction torque sensor (TFF400; 
FUTEK Advanced Sensor Technology, Inc., Irvine, CA, USA), which measured the 
experienced torques and provided an input torque feedback for the system. Along the 
same axis, the arm clamp and the 3-axis inclinometer (3DM-GX3-15; MicroStrain, Inc., 
Williston, VT, USA) were attached on the sensing side of the torque sensor. The 
inclinometer also provided positional feedback as well as measurements for the system. 
The entire assembly was positioned above the rat with the sensing plane parallel to the 
ground to ensure that gravity had little impact on the torque measurements (Figure 3). 
The apparatus was programmed to move to a specified torque or angle for internal and 
external rotation for each rat. Plastic zip ties were used to secure the rat forelimb in the 
apparatus. Care was taken to prevent any injury, and the apparatus was programmed with 
an internal and external kill switch.  
 
Treatment and Measurement of Study Groups 
 Immediately after removal of the restraining sutures, relaxin was administered to 
the noncontrol group rats. These groups were randomly selected for relaxin treatment. 
Relaxin was administered by intra-articular (IA) injection into the anesthetized rats under 
fluoroscopic guidance. Each dose was comprised of 0.0005 mg relaxin diluted in 100 μL 
of phosphate-buffered saline (PBS; 0.0015 mg/kg). Relaxin that was dispensed by 
intravenous (IV) injection through the tail was dosed at 0.17 mg relaxin diluted in 100 μL 
PBS (0.5 mg/kg). In the group that required multiple doses of relaxin, intra-articular and 
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intravenous injections were provided every 2 days over the first 10 days of the post-
immobilization period (5 doses; total relaxin: IA 0.0025 mg, IV 0.85 mg). Injection of 
each intra-articular aliquot of relaxin was performed with a 27-gauge needle 
(PrecisionGlide; Becton, Dickinson and Company, Franklin Lakes, NJ, USA). 
 Subsequent kinematic measurements were performed randomly and in a blinded 
manner after treatment. Each measurement was longitudinally spaced in the follow-up 
period of 8 weeks as determined by a previous study (58). These measurements examined 
the change in ROM, both internal and external angles, given the 𝜏𝐼𝑁𝑇 and 𝜏𝑂𝑈𝑇 recorded 
at baseline. The apparatus was programmed so that each rat was measured on the basis of 
its own individual torque values. This was done to measure any resulting kinematic 
differences by keeping the force required to reach a full ROM consistent for each rat, 
since variation across rats existed (58). Each of these measurements occurred biweekly 
within the first two weeks and then weekly throughout the follow-up period. This 
schedule was done to limit specimen exposure to isoflurane, mainly because during the 
prior experience establishing this model, kinematic changes had been found to occur 
rapidly within the first two weeks and become generally steady for the remainder of the 
period (58). During each measurement period, measurements were taken under anesthesia 
and were repeated three times for both forelimbs to ensure accuracy.  
  
Histological and Radiographic Analysis 
 On the conclusion of the follow-up period, the rats were euthanized according to 
IACUC guidelines. The rats were weighed and then subjected to CO2 exposure for 
 16 
euthanasia, which was subsequently confirmed through a bilateral thoracotomy. The 
shoulders were bilaterally harvested by disarticulating the humerus from the ulna and the 
scapula from the clavicle and thoracic cavity. Any excess muscle tissue not immediately 
surrounding the glenohumeral joint capsule was removed. The excised shoulders were 
decalcified for two months in a solution of ethylenediaminetetraacetic acid (EDTA), 
which was changed every two to three days. Once decalcified, the shoulders were affixed 
in a solution of 10% formalin and then mounted in paraffin stacks for histological 
sectioning at the Beth Israel Deaconess Medical Center (BIDMC) Histology Core. These 
stacks were mounted so that anterior-posterior slicing could be performed on the 
specimens.  The slices were stained with hematoxylin and eosin (H&E) and examined for 
any morphological changes.  
 The specimens chosen to undergo histological analysis were the surgical control 
group and the multiple-dose intra-articular relaxin group. The multiple-dose intra-
articular relaxin group was chosen because this group received the highest and most 
frequent amount of relaxin dosing and would therefore be the best group to showcase any 
changes to the joint space due to relaxin. The contralateral shoulders from the surgical 
control group were used to model a healthy control shoulder for histologic comparisons.  
 
Data and Statistical Analysis 
 Comparisons in kinematic changes were done by comparing the change in ROM 
between the baseline measurement and the measurements that followed immobilization 
and treatment. The change in ROM was calculated using MATLAB script to ensure 
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randomization and blinded data processing for the comparisons. ROM measurements 
were shown as total ROM averages along with standard errors. All variances were 
described by standard errors. Standard error was chosen to represent the precision of the 
population mean as it can be more useful for interpretation in this case rather than 
examining the variation within each group (60). Changes in ROM were examined across 
groups at each measurement time point. Statistical differences across groups and over 
time were performed by repeated measures analysis of variance (ANOVA). Significance 
was determined using an alpha level of 0.01 (P < 0.01). A significance level of 0.01 was 
chosen because it better represented meaningful trends that were observed in this study. 
Histologic images were processed and analyzed using the Fiji distribution of ImageJ (61) 
to measure intra-articular intima thicknesses of the glenohumeral capsule.   
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RESULTS 
Mechanical Testing 
 At the baseline measurement, all rats were measured and attained a full ROM of 
159.17° (0.21°) and a standard deviation of 1.14°, with external measures of 59.58° 
(0.17°) and an internal range of 99.58° (0.14°) with standard deviations of 0.77° and 
0.63°, respectively. Immediately after suture removal from the immobilization period, all 
rats attained a total ROM of 91.17° (4.52°), correlating to a 43.22% (2.82%) total 
reduction from the baseline. Externally and internally, the rats exhibited ranges of 35.96° 
(4.97°) and 55.20° (5.10°), respectively. The rats together had a significant decrease in 
ROM (P < 0.0001), with the control group alone holding a similar significance (P < 
0.0001). At day 0 immediately after immobilization, the multiple-dose intra-articular 
group (P = 0.2721), the single-dose intra-articular group (P = 0.4347), and the multiple-
dose intravenous group (P = 0.6074) were shown to be statistically as restricted as the 
control group.  
At the final time point, the control group attained a total of 130.93° (5.38°) of 
rotation, the multiple-dose intra-articular group measured at 162.27° (3.60°), the single-
dose intra-articular group measured at 138.67° (7.08°), and the multiple-dose intra-
venous group measured at 130.80° (5.02°). Interestingly, the multiple-dose intra-articular 
group ended with a 3.47°, or a 2.17%, increase in ROM from baseline and was found to 
be significantly improved when compared with the control group at P = 0.0013. All other 
groups were not significantly different from the control group (Table 1). The control 
group had a -28.14°, or a -17.59% (P = 0.0048), reduction from baseline measurements. 
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Similarly, the intravenous group displayed a -27.87°, or a -17.42% (P = 0.0056), 
reduction when compared with baseline. The single-dose intra-articular group showed 
more of a slight improvement from baseline with a difference in ROM of -21.46°, or 
-13.41% (P = 0.0385). However, this increase was not found to be a significant 
improvement when compared with the control.   
 Table 1. Final Total Ranges of Motion for Each Groupa 
Group 
Baseline Final Difference 
ROM (°) SEM (°) ROM (°) SEM (°)  ROM (Δ°) Percent P  
Control 159.07 0.61 130.93 5.38 -28.14 -17.59 1.0000 
IA Multiple 158.80 0.48 162.27 3.60 3.47 2.17 0.0013 
IA Single 160.13 0.40 138.67 7.08 -21.46 -13.41 0.4090 
IV Multiple 158.67 0.55 130.80 5.02 -27.87 -17.42 0.9860 
aA complete range of motion is expected to be near 160°. A negative change in ROM describes a 
difference in final ROM that is lower than a full ROM. A positive change indicates a final ROM 
that is greater than the baseline measurement. Significance is determined at 𝛼 = 0.01. The P-
value is the result of a comparison between the final control ROM and the ROM of each of the 
different groups. 
 
     
 On examination of the full ROM data across different time points (Figure 4), the 
multiple-dose intra-articular group appeared to be a significant improvement over the 
control group. The multiple-dose intra-articular group was significantly greater than the 
control group at days 7, 49, and 56 with α = 0.01, and at all days except day 0 and day 21 
with α = 0.05. All other groups showed no significance throughout the time points. For 
the multiple-dose intra-articular group, its variance increased as it approached day 21 and 
decreased thereafter. All other groups did not exhibit any pattern with variance. Another 
important trend to note was the sharp improvement in ROM in the single-dose intra-
articular group immediately after administering relaxin, similar to that of the multiple-
dose intra-articular group. Improvements showed a 29.20° increase in ROM as opposed 
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to only 11.33° seen in the control group. This increase was not significant (P = 0.4213). 
After the second measurement, however, the single-dose intra-articular group began to 
drop and trend below all the other groups for some time. This trend was not found to be 
significantly lower than the control group at any point in time.  
 Additionally, at the final measurement, the multiple-dose intra-articular group 
was statistically similar (P = 0.4304) to its healthy baseline measurement. The single-
dose intra-articular group showed an improvement toward baseline that was ultimately 
not statistically significant (P = 0.0385). Both the intravenous and control groups 
remained significantly worse than the healthy condition at P = 0.0056 and at P = 0.0048, 
respectively. 
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Figure 4. Change in total ROM post-surgery. Results are presented as the means with standard 
errors. The dotted line indicates a healthy ROM, and the vertical dashed line highlights the day of 
suture removal. Significance at 𝛼 = 0.01 is denoted by an asterisk, and significance at 𝛼 = 0.05 
is shown as a cross. 
 
 
 Breaking up the total ROM into external and internal ROMs highlighted the stark 
differences between the two. A closer look at external ROMs noted no major differences 
between the baseline and final measurements (Table 2). The control group had a change 
in ROM of 2.87°, or 1.79%.   The control group also showed no significant difference 
when comparing baseline with the final measurement (P = 0.6199) or when comparing 
day 0 with the final measurement (P = 0.0418).  These results contrasted with the 
significance found within internal rotation, with a significant difference in both day 0 (P 
= 0.0002) and final day measurements (P = 0.0078) when compared with baseline, which 
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suggests to a successful contracture model internally. The absence of a significant 
decrease in ROM for the external rotation case was unexpected from the previous 
stiffness model (58). In comparison, the other groups—multiple-dose intra-articular (P = 
0.7316), single-dose intra-articular (P = 0.6329), and multiple-dose intravenous (P = 
0.2271)—also showed a similar lack of difference from baseline to their final 
measurements.  Based on these findings, external ROM by itself showed negligible 
change in ROM. This was further observed in the temporal data plotted in Figure 5. 
There was, however, one single point at day 7 of measurement that showed a strong 
significant difference when comparing the single-dose intra-articular group and the 
control group (P = 0.0018). Although once the data were aggregated, this significance 
was lost. 
 
Table 2. Final External Ranges of Motion for Each Groupb 
Group 
Baseline Final Difference 
ROM (°) SEM (°) ROM (°) SEM (°)  Range (°) Percent P  
Control 59.33 0.43 62.20 5.27 2.87 1.79 1.0000 
IA Multiple 59.67 0.26 57.13 7.12 -2.53 -1.58 0.5831 
IA Single 60.00 0.32 63.47 6.78 3.47 2.17 0.8863 
IV Multiple 59.33 0.38 50.07 6.74 -9.27 -5.79 0.1940 
b A complete external range of motion is expected to be near 60°. A negative change in ROM 
describes a difference in final ROM that is lower than a full ROM. A positive change indicates a 
final ROM that is greater than the baseline measurement. Significance is determined at 𝛼 = 0.01. 
The P-value is the result of a comparison between the final control ROM and the ROM of each of 
the different groups.  
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Figure 5. Change in external ROM post-surgery. Results are presented as means with standard 
errors. The dotted line indicates a healthy ROM, and the vertical dashed line highlights the day of 
suture removal. Significance at 𝛼 = 0.01 is denoted by an asterisk, and significance at 𝛼 = 0.05 
is shown as a cross. 
 
 
Contrary to external rotation results, the control group for internal rotation 
displayed a significant total decrease in ROM of 31.00°, or 19.38% (P = 0.0078), after 
the final measurement. Additionally, immediately after immobilization, the internal 
rotation of the control group exhibited a decrease of 51.73°, or 51.67% (P = 0.0002) on 
day 0. Each of the other groups was similarly restricted when compared with the control 
group, as indicated by the multiple-dose intra-articular group with P = 0.0875, the single-
dose intra-articular group with P = 0.4621, and the multiple-dose intravenous group with 
P = 0.3627.  At the final measurement, only the multiple-dose intra-articular group was 
shown to have a significant improvement from the control contracture group, with a total 
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range of 105.13°, or a 6.05% improvement (P = 0.0073) (Table 3). This improvement, 
however, was statistically similar to the healthy baseline measurement (P = 0.5142). 
 
Table 3. Final Internal Ranges of Motion for Each Groupc 
Group 
Baseline Final Difference 
ROM (°) SEM (°) ROM (°) SEM (°) Range (°) Percent P 
Control 99.73 0.32 68.73 6.15 -31.00 -31.08 1.0000 
IA Multiple 99.13 0.27 105.13 8.13 6.00 6.05 0.0073 
IA Single 100.13 0.31 75.20 7.42 -24.93 -24.90 0.5213 
IV Multiple 99.33 0.24 80.73 7.90 -18.60 -18.73 0.2651 
c A complete internal range of motion is expected to be near 100°. A negative change in ROM 
describes a difference in final ROM that is lower than a full ROM. A positive change indicates a 
final ROM that is greater than the baseline measurement. Significance is determined at 𝛼 = 0.01. 
The P-value is the result of a comparison between the final control ROM and the ROM of each of 
the different groups. 
 
 At the final time point, the other two groups shared no statistical difference with 
the control group or with  the multiple-dose intra-articular group. The differences from 
the control for single-dose intra-articular and multiple-dose intravenous were very similar 
(Table 3). When compared with the final result of the multiple-dose intra-articular group, 
the single-dose intra-articular group had P = 0.0263, which could be considered 
significant if 𝛼 = 0.05 was used. The intravenous group, however, was not significant at 
either alpha level with P = 0.0636 when compared with the multiple-dose intra-articular 
group.   
 The results for internal ROM (Figure 6) differed from total ROM (Figure 4) in 
that internal ROM did not share as prominent of an increase in ROM immediately after 
day 0. In fact, the increase in the total ROM data was a manifestation of two less obvious 
increases at day 3 in both external and internal ROM data sets. Also, for internal ROM, 
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significance from the control group was only found in the multiple-dose intra-articular 
group on days 42 and 56.  
 
 
Figure 6. Change in internal ROM post-surgery. Results are presented as means with standard 
errors. The dotted line indicates a healthy ROM, and the vertical dashed line highlights the day of 
suture removal. Significance at 𝛼 = 0.01 is denoted by an asterisk, and significance at 𝛼 = 0.05 
is shown as a cross. 
 
 
Histology 
 The H&E stained sections for the surgical control group showed morphological 
changes to the surrounding capsular tissue when compared with the healthy control. As 
seen in Figure 7, the healthy control displayed proper separation between capsule and 
articular surface on the humeral head. The synovial membrane and articular cartilages 
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showed normal cellular organization. However, the surgical control group in Figure 8 
lacked this separation.  
 
  
Figure 7. Coronal H&E stains of the humeral head in a healthy control. Medial and lateral 
directions correspond to the right and the left of the image, respectively. The top of the image is 
the superior direction. (A) Image taken at 2.5x magnification. The scale bar is set to 500 μm. (B) 
Magnified image of the inferior aspect of the humeral head taken from within the outlined box on 
image A. Image taken at 10x magnification. The scale bar is set to 10 μm. 
 
 In the surgical control group, fibrotic adhesions were apparent. The region 
outlined by the box in Figure 8A was the most affected area in the joint. In Figure 8B, 
two arrows delineated the differentiated synovial membrane and articular cartilage. These 
tissues showed the same organization as found in the healthy control. This differentiation 
between the tissues gradually disappeared when approaching the inferior aspect of the 
humeral head. Most inferiorly, the articular surface of the humeral head and the synovial 
membrane lost all differentiation. The membrane and cartilage nuclei failed to maintain a 
tangential orientation to the humeral head within the superficial zone (tangential zone) 
and instead showed directionality that was orthogonal to the expected surface. The 
cellular bodies appeared to be stretched between the capsular membrane and the 
500μm 10μm 
A B 
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cartilaginous surface of the humerus. Evidence of these adhesions was a confirmation of 
the success of the contracture model.  
 
Figure 8. Coronal H&E stains of the humeral head in a surgical control. Medial and lateral 
directions correspond to the right and the left of the image, respectively. The top of the image is 
the superior direction. (A) Image taken at 2.5x magnification. The scale bar is set to 500 μm. (B) 
Magnified image of the inferior aspect of the humeral head taken from within the outlined box on 
image A. Image taken at 10x magnification. The scale bar is set to 10 μm. 
 
 In contrast to the surgical control, the multiple-dose intra-articular relaxin group 
lacked any apparent adhesions (Figure 9). The synovial membrane and articular cartilage 
surfaces remained independent from one another, maintaining proper orientation. Cellular 
organization of these membranes also showed the similar tangential squamous shape that 
was apparent in the healthy control image. Interestingly, the tissue density of the fibrous 
capsular tissue appeared to be less than the density found in the healthy control group. 
Additionally, some discontinuities of the shoulder capsule from the region just below the 
humeral head growth plate were seen, perhaps indicating a tear. An example of this was 
marked by an arrow in Figure 9A. The degradation of the articular cartilage was also 
highlighted by arrows in Figure 9B. This destruction was manifested as a thinning of 
500μm 10μm 
A B 
 28 
articular cartilage thickness in the superficial zone and delamination of the articular 
cartilaginous layers.  
 
Figure 9. Coronal H&E stains of the humeral head in a relaxin-treated shoulder. Medial and 
lateral directions correspond to the right and the left of the image, respectively. The top of the 
image is the superior direction. (A) Image taken at 2.5x magnification. The scale bar is set to 500 
μm. (B) Magnified image of the inferior aspect of the humeral head taken from within the 
outlined box on image A. Image taken at 10x magnification. The scale bar is set to 10 μm. 
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DISCUSSION 
Support for Specific Aims 
Mechanical Testing 
 For the aims of this thesis to be satisfactorily addressed, it is crucial to ensure that 
the animal model being used was properly established and that the mechanical testing 
apparatus achieved the precision (<1% variance) and accuracy (<1% difference from 
baseline) necessary for confidence in the experimental measurements. The model 
achieved both shoulder contracture and prolonged reduction in ROM. The total ROM of 
the rats after immobilization showed a 43.22% reduction from their baseline 
measurements. Additionally, the control group remained 17.59% more restricted than at 
their baseline measurements at the end of 8 weeks, suggesting that the immobilization 
method was a success. This amount of restriction remains consistent with previously run 
models (58, 59). 
 Given the three experimental groups for examining the effects of relaxin, the 
multiple-dose intra-articular relaxin group showed significant improvements above all 
other groups. This group finished with a 2.17% increase in ROM that was still similar to 
its baseline measurement. This finding suggests that the efficacy of relaxin for 
arthrofibrosis does exist, and that there is a potential for its use to fully resolve the ROM 
symptoms of shoulder arthrofibrosis. Although an increase in ROM beyond the baseline 
measurement may be concerning, this evidence further supports the ability of relaxin to 
modify existing collagen structures (50). However, since ROM greater than baseline was 
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achieved in some cases, proper dosing for relaxin must be carefully considered to achieve 
the desired effect.  
 Dosing effects were further observed when examining the single-dose intra-
articular relaxin group. After the first intra-articular injection, although not significant 
from the control group, this group showed a sharp increase in ROM of 29.20° three days 
after injection. Because the injections occurred once every two days in the multiple-dose 
groups, an additional injection in the single-dose intra-articular group would have 
continued this trend for improvement. This result suggests that a prolonged exposure to 
relaxin is necessary for proper recovery from a secondary shoulder contracture. Also of 
importance was the observed decline in ROM after the third day of measurement in the 
single-dose intra-articular group. Not only did this group fail to continue improving, as 
seen in the multiple-dose intra-articular group, but it returned to ROM measures similar 
to that of the control group. This worsening of the ROM after intra-articular injection 
suggests that additional fibrosis may have been caused by either articular trauma induced 
by intra-articular injection or other reasons such as an immune response to exogenous 
relaxin (17, 18).  This decline in ROM continued to decrease up to around 10 days after 
the single-dose intra-articular injection.  
 Further evidence supporting the contribution of articular trauma in worsening of 
ROM can be seen in the multiple-dose intra-articular group. Looking at the variance of 
each measure in this group, the values increased to a maximum on the measurement that 
was approximately 10 days after the final intra-articular injection for the group. This 
timeline fits well with other observations of the development of fibrosis after trauma in 
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rats, in which fibrosis was noticeable after 7-10 days (62, 63). The increase in variance 
may have been due in part to the variability in performing intra-articular injections with a 
27-gauge needle for a small joint space. Based on how well the procedure was done, 
differing amounts of trauma may have been introduced into the rats’ shoulders. Each of 
the rats may additionally have differing responses to this trauma, further compounding 
the variability during this time. However, despite this variability, the group trended 
toward a statistically full recovery and improved well beyond the controls.  
 In addition, the final ROM of the single-dose intra-articular group exhibited 
differences from all the other groups. Although the group did not show a statistically 
improved ROM result when compared with the control for the final measurement, neither 
did the group show any difference from the original baseline measurement (P = 0.0385). 
Though this result was not significantly different at 𝑎 = 0.01, it was significantly 
different at 𝑎 = 0.05. The fact that the final ROM measurement for this group remains a 
nonsignificant improvement from the control group and that it fails to show a strong 
difference from its own baseline measurement, suggests that there may have been an 
improvement in ROM from a single dose of relaxin. Because this improvement cannot be 
said with certainty, this result encourages a further exploration into the proper dosing and 
exposure of relaxin when treating shoulder contractures.   
 The intravenous effects of relaxin showed virtually no significant difference from 
the control group at any time point. Additionally, the intravenous relaxin group 
maintained a similar difference from baseline measurements when compared with the 
control. These results suggest that intravenous relaxin provides no benefit to the 
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betterment of a shoulder contracture. This finding makes sense, particularly because 
relaxin has a short half-life within the systemic circulation. As a result of its rapid 
degradation, relaxin may have too minimal of exposure to the joint area, especially since 
articular capsules are often not well perfused. Considering that intra-articular relaxin 
displayed more of an effect on ROM, it is possible that the joint space provides the 
necessary isolation from the systemic circulation to extend the time of degradation for 
relaxin. Furthermore, because relaxin was injected directly to the area of interest, it can 
also be certain that an appreciable amount reached its target.  
 All of these effects on total ROM were also observed when considering internal 
rotation only. In fact, the effects of relaxin seem to be further emphasized within internal 
rotation. However, this was not the case for external rotation, as all of the results 
remained statistically similar. This result is most likely a response to the limits placed on 
the ROM measurements. For internal rotation, 100° of rotation is not close to the 
physiologic limits of rotation, but 60° of external rotation at forward elevation is near 
physiologic limits (64-66). Earlier studies found that external rotation should display an 
increase in the torque required to reach 60° after immobilization (58), yet an increase in 
torque does not necessarily correlate to a decrease in ROM. In this study, because 60° is 
near the limits of rotation, the application of additional force would result in a minimal 
increase in external ROM. Therefore, although torque might increase for external rotation 
during a shoulder contracture, the torque required to reach 60° was overestimated as a 
result of the baseline measurement already nearing physiologic limits. Thus, this 
overestimation likely caused external ROMs of similar range to be measured despite 
 33 
increases in torque. The opposite is true for internal rotation, and this may be the reason 
why internal rotation showed a better contracture than external rotation.  
Histologic Evidence 
 The histologic data mirror the results found during the mechanical testing. 
Confirming the successful creation of the in vivo shoulder contracture model was the 
presence of fibrotic adhesions in the inferior portion of the capsular space in the surgical 
controls. Additional confirmation for this model came from the expected lack of 
adhesions in the contralateral healthy shoulder.  
 The relaxin histologic images, although much more similar to the healthy control 
images, showed a number of changes between the other two conditions. The fact that the 
relaxin images showed proper differentiation between the synovial membrane and 
articular cartilage suggests that intra-articular relaxin aided a return to a normal 
condition. The surfaces seen in the superficial zone showed the characteristically parallel 
articular cartilage cells against the contour of the bone. In addition, a similarly squamous 
characteristic in the synovial membrane suggests a morphologic return to a normal 
condition. These findings suggest that relaxin may be able to play a role in alleviating 
arthrofibrosis within the shoulder. 
 However, differences from the normal condition did exist. The finding that the 
fibrous tissue comprising the capsular lining seemed to have lost some density may 
actually be a cause for the capsular tear observed in Figure 9. Because relaxin can 
encourage the remodeling and reuptake of collagens I and III, this lack of density may be 
a result of the action of relaxin on the surrounding collagen. This lessening of collagen 
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would result in a weakening of the tensile properties found in highly collagenous tissues 
and would result in tears if excessively stressed. The mechanical testing apparatus causes 
the rats to undergo rotational movement that is not dissimilar to physical therapy. Perhaps 
this force induced through measurement was enough to manifest as a tear within these 
histologic images.  
 This possible collagen degradation was also seen on the articular surface of the 
humerus, where there was a simultaneous thinning of the superficial zone along with 
cellular delamination. This degradation may simply be characteristic of some alterations 
of the articular surface as a result of immobilization (67). However, although it is not 
generally thought that relaxin affects collagen II, altering the level of MMPs within the 
collagen synthesis pathway has been shown to affect articular cartilage (68). If relaxin 
holds the ability to alter the articular surface and surrounding capsular structure within 
joints beyond that of reversing fibrosis, additional care must be taken to evaluate proper 
exposure to relaxin. The evidence, as found by these histological images, suggests that 
excess relaxin may not only reverse the effects of arthrofibrosis but also further degrade 
existing collagen structures.  
 
Limitations 
 As noted in the preceding section, the ROM chosen for external rotation may have 
been too large. It is often expected that in frozen shoulder, external rotation is most 
affected (65). Because the limit of external rotation with forward elevation was 
overestimated in this rat model, it is possible that any effect on the contracture that 
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relaxin may have had would be obfuscated. Despite this problem, relaxin had a great 
effect on internal rotation in a manner that it dominated the results when observing a total 
ROM of 160°. If a smaller external rotation angle were to be chosen, perhaps a similar 
result would be seen externally. As a result, there is the possibility that the effect of 
relaxin in this study was understated.  
 Furthermore, the method of intra-articular injections used in this work included a 
comparatively large gauge needle for navigating the intra-articular space. Because of the 
size, the chance for additional trauma and further fibrosis may have diluted the effects of 
relaxin even more than necessary. Although an intra-articular injection may cause a 
moderate amount of trauma to the joint area, in its typical use, a more appropriately sized 
needle is utilized for humans. This would result in much less trauma than the rats 
experienced in these procedures.  
 Additionally, because the limitations found with the methods in this study could 
work to downplay the effectiveness of relaxin, the dosing duration and concentrations 
would not be representative values for potential treatment. Although it was successfully 
determined that relaxin has a positive effect on shoulder arthrofibrosis, the specifics 
behind delivery and dosing remain uncertain. This study is limited in its ability to rule out 
the ineffectiveness of any of the other drug delivery methods and instead can only 
propose which will work with the given concentrations and frequencies. 
 Although this study holds promising results, another limitation lies in the fact that 
these procedures were conducted in rat shoulders. Rat shoulders differ from human 
shoulders in that they are load-bearing appendages. Therefore, it may be difficult to say 
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how well these results translate to a human, as humans do not rely on their upper 
extremities for locomotion in normal conditions. Also, this study aimed to show the 
efficacy of relaxin in cases of arthrofibrosis, but only the shoulder was examined. Though 
the pathophysiology is similar across cases of arthrofibrosis, there is no guarantee that 
relaxin can be applied directly to another joint case of arthrofibrosis outside the shoulder.   
 
Future Studies 
 Since there were limitations to this study, future work should aim to explore these 
areas further. Although relaxin was shown to alleviate a shoulder contracture in this 
study, further experiments should consider its efficacy in remediating cases of 
arthrofibrosis in other joints. Additionally, these studies may choose to examine relaxin 
in differing species to ensure a similar effect.  
 Also, proper dosing should be established, and further studies may choose to 
explore more efficient concentrations and frequencies for relaxin delivery. This may 
include a low-level, slow-release drug delivery system that reduces the amount of trauma 
introduced into the joint space. Additional evaluations of relaxin should also closely 
examine potential side effects of using relaxin as a treatment for arthrofibrosis, as 
excessive dosing may result in damage to articular joints.  
 
Conclusion 
A repetitive, local intra-articular injection of relaxin into the glenohumeral space 
was found to be effective in resolving the range of motion symptoms that occur in a 
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shoulder contracture and in returning the range of rotation back to a normal condition. 
This result was further supported through histologic evidence which showed no 
pathological fibrosis within the joint space. A single intra-articular injection of relaxin 
and an intravenous injection of relaxin were both ineffective for returning the range of 
motion back to baseline. Although an improvement in shoulder arthrofibrosis was shown 
in this study, further research is necessary to fine-tune the delivery of relaxin for use in 
patients suffering from arthrofibrosis.  
  
 
 
 
 
 
  
 38 
LIST OF JOURNAL ABBREVIATIONS 
Acta Orthop.  ........................................................................................... Acta Orthopaedica 
Adv Exp Med Biol.  ..............................  Advances in Experimental Medicine and Biology 
Am J Sports Med. ..................................................... American Journal of Sports Medicine 
Am J Renal Physiol.  ........................  American Journal of Physiology – Renal Physiology 
Ann R Coll Surg Engl.  .................... Annals of The Royal College of Surgeons of England 
Ann Rheum Dis. ...................................................................Annals of Rheumatic Diseases 
Arch Orthop Trauma Surg. .......................... Archives of Orthopaedic and Trauma Surgery 
Arthritis Rheum .......................................................................... Arthritis & Rheumatology 
Bone Joint J.  ................................................................................ The Bone & Joint Journal 
Br J Anaesth.  .......................................................................  British Journal of Anaesthesia 
Br J Sports Med.  ........................................................... British Journal of Sports Medicine 
Br Med J.  ......................................................................................... British Medical Journal 
Clin Biomech.  .................................................................................. Clinical Biomechanics  
Clin Orthop Relat Res.  ................................... Clinical Orthopaedics and Related Research 
Cochrane Database Syst Rev.  ................... The Cochrane Database of Systematic Reviews 
Exp Ther Med.  ..................................................... Experimental and Therapeutic Medicine 
Int Orthop .................................................................................... International Orthopaedics 
J Bone Joint Surg Br.  .................................. The Journal of Bone and Joint Surgery British 
J Brachial Plex Peripher Nerve Inj. Journal of Brachial Plexus and Peripheral Nerve Injury 
J Rheumatol.  ......................................................................... The Journal of Rheumatology 
J Shoulder Elbow Surg. ......................................... Journal of Shoulder and Elbow Surgery 
 39 
Knee Surg Sports Traumatol Arthrosc.  .. Knee Surgery, Sports Traumatology, Arthoscopy 
Muscles Ligaments Tendons J ........................... Muscles, Ligaments, and Tendons Journal 
N Am J Sports Phys Ther. ................. North American Journal of Sports Physical Therapy 
Nat Methods.  .............................................................................................. Nature Methods  
Open Orthop J.  ................................................................... The Open Orthopaedics Journal 
Orthop Clin North Am ............................................... Orthopedic Clinics of North America 
Osteoarthritis Cartilage ............................................................. Osteoarthritis and Cartilage 
Pharm Res.  ..................................................................................  Pharmaceutical Research 
Phys Ther.  .................................. The Journal of Orthopaedic and Sports Physical Therapy 
Protein Pept Lett.  ......................................................................... Protein & Peptide Letters 
Rheumatol Rehabil. .........................................................Rheumatology and Rehabilitation 
Saudi J Anaesth. ...................................................................... Saudi Journal of Anaesthesia 
Shoulder & Elbow..................................................... Journal of Shoulder & Elbow Surgery 
Transl Res.  ....................................................................................... Translational Research 
Traumatol Rehabil.  ................. Journal of Orthopaedics, Traumatology and Rehabilitation 
 
 
 
 
  
 40 
REFERENCES 
1. Le HV, Lee SJ, Nazarian A, Rodriguez EK. Adhesive capsulitis of the shoulder: 
review of pathophysiology and current clinical treatments. Shoulder & Elbow. 
2016:175857321667678. 
 
2. Millett PJ, Williams RJ, 3rd, Wickiewicz TL. Open debridement and soft tissue 
release as a salvage procedure for the severely arthrofibrotic knee. Am J Sports Med. 
1999;27(5):552-61. 
 
3. Maloney MD, Sauser DD, Hanson EC, Wood VE, Thiel AE. Adhesive capsulitis 
of the wrist: arthrographic diagnosis. Radiology. 1988;167(1):187-90. 
 
4. Neviaser AS, Hannafin JA. Adhesive capsulitis: a review of current treatment. 
Am J Sports Med. 2010;38(11):2346-56. 
 
5. Gittings D, Hesketh P, Dattilo J, Zgonis M, Kelly J, Mehta S. Arthroscopic lysis 
of adhesions improves knee range of motion after fixation of intra-articular fractures 
about the knee. Arch Orthop Trauma Surg. 2016;136(12):1631-5. 
 
6. Cosgarea AJ, DeHaven KE, Lovelock JE. The surgical treatment of arthrofibrosis 
of the knee. Am J Sports Med. 1994;22(2):184-91. 
 
7. Kalson NS, Borthwick LA, Mann DA, Deehan DJ, Lewis P, Mann C, et al. 
International consensus on the definition and classification of fibrosis of the knee joint. 
Bone Joint J. 2016;98-B(11):1479-88. 
 
8. Walker-Bone K, Palmer KT, Reading I, Coggon D, Cooper C. Prevalence and 
impact of musculoskeletal disorders of the upper limb in the general population. Arthritis 
Rheum. 2004;51(4):642-51. 
 
9. Nagy MT, Macfarlane RJ, Khan Y, Waseem M. The frozen shoulder: myths and 
realities. Open Orthop J. 2013;7:352-5. 
 
10. Wang JP, Huang TF, Ma HL, Hung SC, Chen TH, Liu CL. Manipulation under 
anaesthesia for frozen shoulder in patients with and without non-insulin dependent 
diabetes mellitus. Int Orthop. 2010;34(8):1227-32. 
 
11. Hsu JE, Anakwenze OA, Warrender WJ, Abboud JA. Current review of adhesive 
capsulitis. J Shoulder Elbow Surg. 2011;20(3):502-14. 
 
12. Binder AI, Bulgen DY, Hazleman BL, Roberts S. Frozen shoulder: a long-term 
prospective study. Ann Rheum Dis. 1984;43(3):361-4. 
 
 41 
13. Bunker TD. Time for a new name for 'frozen shoulder'. Br Med J (Clin Res Ed). 
1985;290(6477):1233-4. 
 
14. Bunker TD, Anthony PP. The pathology of frozen shoulder. A Dupuytren-like 
disease. J Bone Joint Surg Br. 1995;77(5):677-83. 
 
15. Kilian O, Kriegsmann J, Berghauser K, Stahl JP, Horas U, Heerdegen R. [The 
frozen shoulder. Arthroscopy, histological findings and transmission electron microscopy 
imaging]. Chirurg. 2001;72(11):1303-8. 
 
16. Harvard Medical School. Frozen Shoulder. Harvard Health Publications 
[Internet]. 2014 February 22, 2017. Available from: 
http://www.health.harvard.edu/shoulders/frozen-shoulder. 
 
17. Sharma S. Management of frozen shoulder - conservative vs surgical? Ann R Coll 
Surg Engl. 2011;93(5):343-4; discussion 5-6. 
 
18. Sheridan MA, Hannafin JA. Upper extremity: emphasis on frozen shoulder. 
Orthop Clin North Am. 2006;37(4):531-9. 
 
19. Robinson CM, Seah KT, Chee YH, Hindle P, Murray IR. Frozen shoulder. J Bone 
Joint Surg Br. 2012;94(1):1-9. 
 
20. Hand GC, Athanasou NA, Matthews T, Carr AJ. The pathology of frozen 
shoulder. J Bone Joint Surg Br. 2007;89(7):928-32. 
 
21. Hand C, Clipsham K, Rees JL, Carr AJ. Long-term outcome of frozen shoulder. J 
Shoulder Elbow Surg. 2008;17(2):231-6. 
 
22. Shaffer B, Tibone JE, Kerlan RK. Frozen shoulder. A long-term follow-up. J 
Bone Joint Surg Am. 1992;74(5):738-46. 
 
23. Green S, Buchbinder R, Hetrick S. Physiotherapy interventions for shoulder pain. 
Cochrane Database Syst Rev. 2003(2):CD004258. 
 
24. Vermeulen HM, Rozing PM, Obermann WR, le Cessie S, Vliet Vlieland TP. 
Comparison of high-grade and low-grade mobilization techniques in the management of 
adhesive capsulitis of the shoulder: randomized controlled trial. Phys Ther. 
2006;86(3):355-68. 
 
25. Diercks RL, Stevens M. Gentle thawing of the frozen shoulder: a prospective 
study of supervised neglect versus intensive physical therapy in seventy-seven patients 
with frozen shoulder syndrome followed up for two years. J Shoulder Elbow Surg. 
2004;13(5):499-502. 
 42 
 
26. Lho YM, Ha E, Cho CH, Song KS, Min BW, Bae KC, et al. Inflammatory 
cytokines are overexpressed in the subacromial bursa of frozen shoulder. J Shoulder 
Elbow Surg. 2013;22(5):666-72. 
 
27. Rhind V, Downie WW, Bird HA, Wright V, Engler C. Naproxen and 
indomethacin in periarthritis of the shoulder. Rheumatol Rehabil. 1982;21(1):51-3. 
 
28. Bulgen DY, Binder AI, Hazleman BL, Dutton J, Roberts S. Frozen shoulder: 
prospective clinical study with an evaluation of three treatment regimens. Ann Rheum 
Dis. 1984;43(3):353-60. 
 
29. Harris JD, Griesser MJ, Copelan A, Jones GL. Treatment of adhesive capsulitis 
with intra-articular hyaluronate: A systematic review. Int J Shoulder Surg. 2011;5(2):31-
7. 
 
30. Ozkan K, Ozcekic AN, Sarar S, Cift H, Ozkan FU, Unay K. Suprascapular nerve 
block for the treatment of frozen shoulder. Saudi J Anaesth. 2012;6(1):52-5. 
 
31. Dahan TH, Fortin L, Pelletier M, Petit M, Vadeboncoeur R, Suissa S. Double 
blind randomized clinical trial examining the efficacy of bupivacaine suprascapular nerve 
blocks in frozen shoulder. J Rheumatol. 2000;27(6):1464-9. 
 
32. Watson L, Bialocerkowski A, Dalziel R, Balster S, Burke F, Finch C. 
Hydrodilatation (distension arthrography): a long-term clinical outcome series. Br J 
Sports Med. 2007;41(3):167-73. 
 
33. Sharma RK, Bajekal RA, Bhan S. Frozen shoulder syndrome. A comparison of 
hydraulic distension and manipulation. Int Orthop. 1993;17(5):275-8. 
 
34. Buchbinder R, Green S, Forbes A, Hall S, Lawler G. Arthrographic joint 
distension with saline and steroid improves function and reduces pain in patients with 
painful stiff shoulder: results of a randomised, double blind, placebo controlled trial. Ann 
Rheum Dis. 2004;63(3):302-9. 
 
35. D'Orsi GM, Via AG, Frizziero A, Oliva F. Treatment of adhesive capsulitis: a 
review. Muscles Ligaments Tendons J. 2012;2(2):70-8. 
 
36. Loew M, Heichel TO, Lehner B. Intraarticular lesions in primary frozen shoulder 
after manipulation under general anesthesia. J Shoulder Elbow Surg. 2005;14(1):16-21. 
 
37. Magnussen RA, Taylor DC. Glenoid fracture during manipulation under 
anesthesia for adhesive capsulitis: a case report. J Shoulder Elbow Surg. 2011;20(3):e23-
6. 
 43 
 
38. Placzek JD, Roubal PJ, Freeman DC, Kulig K, Nasser S, Pagett BT. Long-term 
effectiveness of translational manipulation for adhesive capsulitis. Clin Orthop Relat Res. 
1998(356):181-91. 
 
39. Melzer C, Wallny T, Wirth CJ, Hoffmann S. Frozen shoulder--treatment and 
results. Arch Orthop Trauma Surg. 1995;114(2):87-91. 
 
40. Janda DH, Hawkins RJ. Shoulder manipulation in patients with adhesive 
capsulitis and diabetes mellitus: A clinical note. J Shoulder Elbow Surg. 1993;2(1):36-8. 
 
41. Diwan DB, Murrell GA. An evaluation of the effects of the extent of capsular 
release and of postoperative therapy on the temporal outcomes of adhesive capsulitis. 
Arthroscopy. 2005;21(9):1105-13. 
 
42. Snow M, Boutros I, Funk L. Posterior arthroscopic capsular release in frozen 
shoulder. Arthroscopy. 2009;25(1):19-23. 
 
43. Jerosch J. 360 degrees arthroscopic capsular release in patients with adhesive 
capsulitis of the glenohumeral joint--indication, surgical technique, results. Knee Surg 
Sports Traumatol Arthrosc. 2001;9(3):178-86. 
 
44. Smith CD, Hamer P, Bunker TD. Arthroscopic capsular release for idiopathic 
frozen shoulder with intra-articular injection and a controlled manipulation. Ann R Coll 
Surg Engl. 2014;96(1):55-60. 
 
45. Mubark IM, Ragab AH, Nagi AA, Motawea BA. Evaluation of the results of 
management of frozen shoulder using the arthroscopic capsular release. Ortop Traumatol 
Rehabil. 2015;17(1):21-8. 
 
46. Le Lievre HM, Murrell GA. Long-term outcomes after arthroscopic capsular 
release for idiopathic adhesive capsulitis. J Bone Joint Surg Am. 2012;94(13):1208-16. 
 
47. Mehta SS, Singh HP, Pandey R. Comparative outcome of arthroscopic release for 
frozen shoulder in patients with and without diabetes. Bone Joint J. 2014;96-B(10):1355-
8. 
 
48. Ozaki J, Nakagawa Y, Sakurai G, Tamai S. Recalcitrant chronic adhesive 
capsulitis of the shoulder. Role of contracture of the coracohumeral ligament and rotator 
interval in pathogenesis and treatment. J Bone Joint Surg Am. 1989;71(10):1511-5. 
 
49. Omari A, Bunker TD. Open surgical release for frozen shoulder: surgical findings 
and results of the release. J Shoulder Elbow Surg. 2001;10(4):353-7. 
 
 44 
50. Bennett RG. Relaxin and its role in the development and treatment of fibrosis. 
Transl Res. 2009;154(1):1-6. 
 
51. Hagiwara Y, Ando A, Onoda Y, Takemura T, Minowa T, Hanagata N, et al. 
Coexistence of fibrotic and chondrogenic process in the capsule of idiopathic frozen 
shoulders. Osteoarthritis Cartilage. 2012;20(3):241-9. 
 
52. Bunker TD, Reilly J, Baird KS, Hamblen DL. Expression of growth factors, 
cytokines and matrix metalloproteinases in frozen shoulder. J Bone Joint Surg Br. 
2000;82(5):768-73. 
 
53. Chan LJ, Hossain MA, Samuel CS, Separovic F, Wade JD. The relaxin peptide 
family--structure, function and clinical applications. Protein Pept Lett. 2011;18(3):220-9. 
 
54. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, Mak J, et al. 
Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen 
production and reverses cardiac fibrosis in vivo. Endocrinology. 2004;145(9):4125-33. 
 
55. Samuel CS, Lekgabe ED, Mookerjee I. The effects of relaxin on extracellular 
matrix remodeling in health and fibrotic disease. Adv Exp Med Biol. 2007;612:88-103. 
 
56. McDonald GA, Sarkar P, Rennke H, Unemori E, Kalluri R, Sukhatme VP. 
Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates 
renal fibrosis in vivo. Am J Physiol Renal Physiol. 2003;285(1):F59-67. 
 
57. Ferraiolo BL, Winslow J, Laramee G, Celniker A, Johnston P. The 
pharmacokinetics and metabolism of human relaxins in rhesus monkeys. Pharm Res. 
1991;8(8):1032-8. 
 
58. Villa-Camacho JC, Okajima S, Perez-Viloria ME, Walley KC, Zurakowski D, 
Rodriguez EK, et al. In vivo kinetic evaluation of an adhesive capsulitis model in rats. J 
Shoulder Elbow Surg. 2015;24(11):1809-16. 
 
59. Kanno A, Sano H, Itoi E. Development of a shoulder contracture model in rats. J 
Shoulder Elbow Surg. 2010;19(5):700-8. 
 
60. Nagele P. Misuse of standard error of the mean (SEM) when reporting variability 
of a sample. A critical evaluation of four anaesthesia journals. Br J Anaesth. 
2003;90(4):514-6. 
 
61. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. 
Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676-
82. 
 
 45 
62. Karadayi S, Sahin E, Nadir A, Tuncer E, Silig Y, Korkmaz I, et al. Investigation 
of wound healing in rat lung tissues in the postpartum period. Exp Ther Med. 
2012;3(5):807-10. 
 
63. Winkler T, von Roth P, Matziolis G, Schumann MR, Hahn S, Strube P, et al. 
Time course of skeletal muscle regeneration after severe trauma. Acta Orthop. 
2011;82(1):102-11. 
 
64. Blaauw G, Muhlig RS. Measurement of external rotation of the shoulder in 
patients with obstetric brachial plexus palsy. J Brachial Plex Peripher Nerve Inj. 
2012;7(1):8. 
 
65. Page P, Labbe A. Adhesive capsulitis: use the evidence to integrate your 
interventions. N Am J Sports Phys Ther. 2010;5(4):266-73. 
 
66. Stokdijk M, Eilers PH, Nagels J, Rozing PM. External rotation in the 
glenohumeral joint during elevation of the arm. Clin Biomech (Bristol, Avon). 
2003;18(4):296-302. 
 
67. Nagai M, Aoyama T, Ito A, Tajino J, Iijima H, Yamaguchi S, et al. Alteration of 
cartilage surface collagen fibers differs locally after immobilization of knee joints in rats. 
J Anat. 2015;226(5):447-57. 
 
68. Kapila S, Wang W, Uston K. Matrix metalloproteinase induction by relaxin 
causes cartilage matrix degradation in target synovial joints. Ann N Y Acad Sci. 
2009;1160:322-8. 
 
 
 
 
 
 46 
CURRICULUM VITAE 
 47 
 48 
